Skip to main content
Erschienen in:

01.07.2005 | Leitthema

Erstlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)

verfasst von: Dr. M. Reck, N. Niederle, M. Thomas, U. Gatzemeier

Erschienen in: Die Onkologie | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Kombinationschemotherapie stellt den Behandlungsstandard des kleinzelligen Lungenkarzinoms dar. Etablierte Chemotherapieschemata sind Cisplatin/Etoposid (PE), Carboplatin/Etoposid/Vincristin (CEV), Cyclophosphamid/Adriamycin/Vincristin (CAV, ACO) sowie Adriamycin, Cyclophosphamid, Etoposid (ACE). Im Stadium I–III der Erkrankung wird die Chemotherapie durch die thorakale Radiotherapie ergänzt, die möglichst frühzeitig (simultan zur Chemotherapie) eingeleitet werden sollte. In diesem Fall wird simultan zur Radiotherapie die Kombination aus Cisplatin/Etoposid (PE) eingesetzt. Für die Effektivität der Kombinationschemotherapie ist das Einhalten des therapeutischen Intervalls bedeutsam. Die Eskalation der Zytostatika im konventionellen Dosisbereich bzw. bis hin zur Hochdosischemotherapie führte in den bisherigen Studien zu keinem Überlebensvorteil. Aktive neue Substanzen, die die therapeutische Bandbreite beim kleinzelligen Lungenkarzinom erweitern und derzeit überprüft werden, sind die Topoisomerase-I-Inhibitoren Topotecan und Irinotecan. Eine kontinuierliche systemische Erhaltungstherapie — sei es in Form von Zytostatika, von Metalloproteinaseinhibitoren oder immunologischen Therapiemaßnahmen — war bisher ohne erkennbaren Vorteil.
Literatur
1.
Zurück zum Zitat Ferlay J, Bray F, Pisani P, Parkin D (2001) Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press Ferlay J, Bray F, Pisani P, Parkin D (2001) Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press
2.
Zurück zum Zitat Levi F, Lucchini F, Negri E et al. (1999) Cancer mortality in Europe, 1990–1994 and an overview of trends from 1955 to 1994. Eur J Cancer 35:1477–1516CrossRefPubMed Levi F, Lucchini F, Negri E et al. (1999) Cancer mortality in Europe, 1990–1994 and an overview of trends from 1955 to 1994. Eur J Cancer 35:1477–1516CrossRefPubMed
3.
Zurück zum Zitat Khuder SA, Mutgi AB (2001) Effect of smoking cessation on major histologic types of lung cancer. Chest 120:1577–1583CrossRefPubMed Khuder SA, Mutgi AB (2001) Effect of smoking cessation on major histologic types of lung cancer. Chest 120:1577–1583CrossRefPubMed
4.
Zurück zum Zitat Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:31–42 Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:31–42
5.
Zurück zum Zitat Wittekind CH, Wagner G (Hrsg) für die UICC (1997) TNM Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New-York Wittekind CH, Wagner G (Hrsg) für die UICC (1997) TNM Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New-York
6.
Zurück zum Zitat Stahel RA, Ginsberg R, Havemann K et al. (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126CrossRef Stahel RA, Ginsberg R, Havemann K et al. (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126CrossRef
7.
Zurück zum Zitat Deutsche Krebsgesellschaft. Therapie des kleinzelligen Lungenkarzinoms aus Kurzgefasste Interdisziplinäre Leitlinien 2004, Diagnostik und Therapie maligner Erkrankungen. Zuckschwerdt, München Bern Wien New York, S 101–113 Deutsche Krebsgesellschaft. Therapie des kleinzelligen Lungenkarzinoms aus Kurzgefasste Interdisziplinäre Leitlinien 2004, Diagnostik und Therapie maligner Erkrankungen. Zuckschwerdt, München Bern Wien New York, S 101–113
8.
Zurück zum Zitat Lassen UN, Hirsch FR, Osterlind K et al. (1998) Outcome of combination chemotherapy in extensive stage small cell lung cancer: any treatment related progress? Lung Cancer 20:151–160CrossRefPubMed Lassen UN, Hirsch FR, Osterlind K et al. (1998) Outcome of combination chemotherapy in extensive stage small cell lung cancer: any treatment related progress? Lung Cancer 20:151–160CrossRefPubMed
9.
Zurück zum Zitat Sandler AB (2003) Chemotherapy for Small Cell Lung Cancer. Seminars in Oncology 30:9–25CrossRef Sandler AB (2003) Chemotherapy for Small Cell Lung Cancer. Seminars in Oncology 30:9–25CrossRef
10.
Zurück zum Zitat Erridge SC, Murray N (2003) Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: Issues of Timing, Volumes, Dose and Fractionation. Semin Oncol 30:26–37CrossRef Erridge SC, Murray N (2003) Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: Issues of Timing, Volumes, Dose and Fractionation. Semin Oncol 30:26–37CrossRef
11.
Zurück zum Zitat Fried DB, Morris DE, Poole C et al. (2004) Systematic Review Evaluating Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 22:4785–4793 Fried DB, Morris DE, Poole C et al. (2004) Systematic Review Evaluating Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 22:4785–4793
12.
Zurück zum Zitat Fukuoka M, Furuse K, Saijo N et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861PubMed Fukuoka M, Furuse K, Saijo N et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861PubMed
13.
Zurück zum Zitat Sundstrøm S, Bremnes RM, Kaasa S et al. (2002) Cisplatin and Etoposide Regimen is Superior to Cyclophosphamide, Epirubicin, and Vincristine in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years‘ Follow-Up. J Clin Oncol 20:4665–4672 Sundstrøm S, Bremnes RM, Kaasa S et al. (2002) Cisplatin and Etoposide Regimen is Superior to Cyclophosphamide, Epirubicin, and Vincristine in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years‘ Follow-Up. J Clin Oncol 20:4665–4672
14.
Zurück zum Zitat Wolf M, Tebbe S, Fink T (2004) First-Line Chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 45 [Suppl 2]:223–234 Wolf M, Tebbe S, Fink T (2004) First-Line Chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 45 [Suppl 2]:223–234
15.
Zurück zum Zitat Stupp R, Monnerat C, Turrisi AT III et al. (2004) Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45:105–117CrossRefPubMed Stupp R, Monnerat C, Turrisi AT III et al. (2004) Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45:105–117CrossRefPubMed
16.
Zurück zum Zitat Schiller JH, Adak S, Cell D et al. (2001) Topotecan versus observation after cisplatin plus etoposide in extensive small-cell lung cancer: E7593 — A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114–2122 Schiller JH, Adak S, Cell D et al. (2001) Topotecan versus observation after cisplatin plus etoposide in extensive small-cell lung cancer: E7593 — A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114–2122
17.
Zurück zum Zitat Hanna H, Sandler AB, Loehrer PJ et al. (2002) Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 13:642–650CrossRef Hanna H, Sandler AB, Loehrer PJ et al. (2002) Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 13:642–650CrossRef
18.
Zurück zum Zitat Niederle N, Krischke W, Schulz U et al. (1982) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Lungenkarzinom. Klin Wochenschrift 60:829–838 Niederle N, Krischke W, Schulz U et al. (1982) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Lungenkarzinom. Klin Wochenschrift 60:829–838
19.
Zurück zum Zitat Steward WP, von Pawel J, Gatzemeier U et al. (1998) Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16:642–650 Steward WP, von Pawel J, Gatzemeier U et al. (1998) Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16:642–650
20.
Zurück zum Zitat Thatcher N, Girling DJ, Hopwood P et al. (2000) Improving survival without reducing quality of life in small cell lung cancer patients by increasing the dose intensity of chemotherapy with granulocyte colony stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 18:395–404 Thatcher N, Girling DJ, Hopwood P et al. (2000) Improving survival without reducing quality of life in small cell lung cancer patients by increasing the dose intensity of chemotherapy with granulocyte colony stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 18:395–404
21.
Zurück zum Zitat Ardizzoni A, Tjan-Heijnen V, Postmus P et al. (2002) Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer – Lung Cancer Group phase III trial — 08923. J Clin Oncol 20:3947–3955 Ardizzoni A, Tjan-Heijnen V, Postmus P et al. (2002) Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer – Lung Cancer Group phase III trial — 08923. J Clin Oncol 20:3947–3955
22.
Zurück zum Zitat Sculier JP, Paesmans M, Lecomte J et al., European Lung Cancer Working Party (2001) A three-arm phase III randomised trial assessing, in patients extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor oral antibiotics. Br J Cancer 85:1444–1451CrossRefPubMed Sculier JP, Paesmans M, Lecomte J et al., European Lung Cancer Working Party (2001) A three-arm phase III randomised trial assessing, in patients extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor oral antibiotics. Br J Cancer 85:1444–1451CrossRefPubMed
23.
Zurück zum Zitat James L, Rudd R, Gower N et al. (2002) A phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 21:2193 (# 1170) James L, Rudd R, Gower N et al. (2002) A phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 21:2193 (# 1170)
24.
Zurück zum Zitat Noda K, Nishiwaki Y, Kawahara M et al., Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91CrossRefPubMed Noda K, Nishiwaki Y, Kawahara M et al., Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91CrossRefPubMed
25.
Zurück zum Zitat Gervais R, Quoix E, Breton J et al. (2001) Randomised phase II study of topotecan/cisplatin (TC) versus topotecan/etoposide (TE) in patients with untreated, extensive disease, small cell lung cancer. Proc Am Soc Clin Oncol 20:#1268 Gervais R, Quoix E, Breton J et al. (2001) Randomised phase II study of topotecan/cisplatin (TC) versus topotecan/etoposide (TE) in patients with untreated, extensive disease, small cell lung cancer. Proc Am Soc Clin Oncol 20:#1268
26.
Zurück zum Zitat Reck M, Jagos U, Grunwald F et al. (2003) Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide — A phase II study. Am Soc Clin Oncol Lung Cancer 39:63–69 Reck M, Jagos U, Grunwald F et al. (2003) Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide — A phase II study. Am Soc Clin Oncol Lung Cancer 39:63–69
27.
Zurück zum Zitat Reck M, von Pawel J, Macha HN et al. (2003) Randomized Phase III Trial of Paclitaxel, Etoposide and Carboplatin versus Carboplatin, Etoposide and Vincristine in Patients with Small-Cell Lung Cancer. J Natl Cancer Inst 95:1118–1127PubMed Reck M, von Pawel J, Macha HN et al. (2003) Randomized Phase III Trial of Paclitaxel, Etoposide and Carboplatin versus Carboplatin, Etoposide and Vincristine in Patients with Small-Cell Lung Cancer. J Natl Cancer Inst 95:1118–1127PubMed
28.
Zurück zum Zitat Mavroudis D, Papadakis E, Veslemes M et al. (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12:463–470CrossRefPubMed Mavroudis D, Papadakis E, Veslemes M et al. (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12:463–470CrossRefPubMed
29.
Zurück zum Zitat Niell HB, Herndon JE, Miller AA et al. (2002) Randomized phase III intergroup trial (CALGB 7932) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer (ED SCLC). Proc Am Soc Clin Oncol 21:#1169 Niell HB, Herndon JE, Miller AA et al. (2002) Randomized phase III intergroup trial (CALGB 7932) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer (ED SCLC). Proc Am Soc Clin Oncol 21:#1169
30.
Zurück zum Zitat Shepherd FA, Giaccone G, Seymour L et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institue of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434–4439 Shepherd FA, Giaccone G, Seymour L et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institue of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434–4439
31.
Zurück zum Zitat Rigas J, Denham C, Rinaldi D et al. (2003) Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY 12–9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:628 (#2525) Rigas J, Denham C, Rinaldi D et al. (2003) Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY 12–9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:628 (#2525)
32.
Zurück zum Zitat Johnson B, Fisher B, Fisher T, Dunlop D et al. (2002) Phase II study of STI571 (GleevecTM) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:293a (#1171) Johnson B, Fisher B, Fisher T, Dunlop D et al. (2002) Phase II study of STI571 (GleevecTM) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:293a (#1171)
33.
Zurück zum Zitat Heymach JV, De Porre PM, DeVore RF et al. (2002) Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 21:319a (#1275) Heymach JV, De Porre PM, DeVore RF et al. (2002) Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 21:319a (#1275)
34.
Zurück zum Zitat Krug LM, Crapanzano JP, Miller VA et al. (2004) C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial. Proc Am Soc Clin Oncol 23: #7218 Krug LM, Crapanzano JP, Miller VA et al. (2004) C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial. Proc Am Soc Clin Oncol 23: #7218
35.
Zurück zum Zitat Rudin CM MK, Hoffman PC, Edelman MJ et al. (2004) Phase I study of G3139, a bcl-2 Antisense Oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110–1117CrossRefPubMed Rudin CM MK, Hoffman PC, Edelman MJ et al. (2004) Phase I study of G3139, a bcl-2 Antisense Oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110–1117CrossRefPubMed
36.
Zurück zum Zitat Giaccone G, Debruyne C, Felip E et al. (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC), following reponse to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). Proc Am Soc Clin Oncol 23:#7020 Giaccone G, Debruyne C, Felip E et al. (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC), following reponse to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). Proc Am Soc Clin Oncol 23:#7020
37.
Zurück zum Zitat Livingston RB, Moore TN, Heilbrun L et al. (1978) Small cell carcinomas of the lung. Combined chemotherapy and radiation. A Southwest Group Study inn. Intern Med 88:194 Livingston RB, Moore TN, Heilbrun L et al. (1978) Small cell carcinomas of the lung. Combined chemotherapy and radiation. A Southwest Group Study inn. Intern Med 88:194
38.
Zurück zum Zitat Klastersky J, Sculier JP, Dumont JP (1986) Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. Cancer 56:71–75 Klastersky J, Sculier JP, Dumont JP (1986) Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. Cancer 56:71–75
39.
Zurück zum Zitat Gatzemeier U, Hossfeld DK, Neuhauss R et al. (1992) Combination Chemotherapy with Carboplatin, Etoposide and Vincristin as First-Line Treatment in Small-Cell Lung Cancer. J Clin Oncol 10:818–823 Gatzemeier U, Hossfeld DK, Neuhauss R et al. (1992) Combination Chemotherapy with Carboplatin, Etoposide and Vincristin as First-Line Treatment in Small-Cell Lung Cancer. J Clin Oncol 10:818–823
Metadaten
Titel
Erstlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)
verfasst von
Dr. M. Reck
N. Niederle
M. Thomas
U. Gatzemeier
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 7/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0887-4

Weitere Artikel der Ausgabe 7/2005

Der Onkologe 7/2005 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.